Leadership

Proven executives with successful exits, pharmaceutical commercialisation, and global market experience.

Viropin Team

  • Darcy Schack, Chief Executive Officer

    A disruptive innovator with a background in engineering and physics from Canada's oil industry. Co-founder of Zestt Wellness and Viropin Pharmaceutical, driven by a personal health journey and a commitment to solutions that materially improve patient outcomes.

  • Dr Anna Campbell, Chief Innovation Officer

    PhD in Biotechnology. Former Managing Director of AbacusBio, an international genetics company, she helped expand into 22 countries. Co-founder of Zestt Wellness and Viropin Pharmaceutical. Extensive commercial experience across the UK, Australia, the Middle East, China, and India.

  • Andrew Cotterill, Chief Commercial Officer

    International operations and market development specialist. Previously led export development across the Middle East, Asia, and North America for one of the world's largest fresh produce companies. Co-founder of SCARAB Group, a UAE-based investment firm. Based in Dubai since 2019, leading Viropin's international expansion strategy.

  • Mike Healy, Chief Financial Officer

    Senior finance executive with significant experience across Life Sciences, including Sandoz, Apotex, Synthes, Boston Scientific, and Eli Lilly. Demonstrated experience in board governance and management, serving as a director of Australian employers and independent entities since 2000.

  • Dr Paul Spence, Chief Scientific Officer

    DPhil in Molecular Virology, University of Oxford. Experienced in commercialising scientific innovation from big pharma to VC-backed startups. Conceived, designed, and executed the production of a dual HIV antigen diagnostic kit, and led multi-million-dollar collaborations to develop new drug targets for CNS disorders. One of the original inventors of NAMZARIC®, a combination drug product for the treatment of Alzheimer's disease.

  • Dr Greg Cook, Lead Microbiologist

    Deputy Vice-Chancellor (Research & Innovation), University of Otago. World-leading microbiologist specialising in bacterial physiology and antimicrobial resistance. Global expert in tuberculosis and bacterial energetics as a new target space for drug development.

  • Lisa Shi, Director, China

    Specialist in international trade with extensive knowledge of China market regulations and access. Master of Arts, University of Auckland.

  • Danny Chan, Director.

    Investor and director. Third-generation New Zealand Chinese, BCA with Honours from Victoria University of Wellington. Multiple directorships across private and public New Zealand companies.